- Conditions
- Psychotic Disorders
- Interventions
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 19 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- ziprasidone vs risperidone or olanzapine
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
- Conditions
- Schizophrenia
- Interventions
- Ziprasidone
- Drug
- Lead sponsor
- North Suffolk Mental Health Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Treatment-resistant Schizophrenia
- Interventions
- Clozapine, Antipsychotics,Other (non-Clozapine)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Schizophrenia and Schizoaffective Disorder
- Interventions
- Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
- Interventions
- risperidone, olanzapine, quetiapine, ziprasidone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 2
- States / cities
- St Louis, Missouri
- Conditions
- Hyperglycemia, Hyperlipidemia
- Interventions
- Olanzapine, Ziprasidone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Interventions
- olanzapine, ziprasidone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 30
- States / cities
- Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
- Conditions
- Schizophrenia
- Interventions
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
- Other · Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 34
- States / cities
- Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
- Conditions
- Schizophrenia
- Interventions
- ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 27
- States / cities
- Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
- Conditions
- Antipsychotics, Pregnancy
- Interventions
- Antipsychotics, Non-antipsychotic medication, No Medication
- Drug · Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Weight Gain, Psychotropic Induced Weight Gain
- Interventions
- Metformin
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Interventions
- Switch, Control
- Drug
- Lead sponsor
- Veterans Medical Research Foundation
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
- Drug
- Lead sponsor
- Matt Byerly
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia
- Interventions
- Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Schizophrenia
- Interventions
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Schizophrenia, Type 2 Diabetes Mellitus
- Interventions
- Ziprasidone, Olanzapine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Psychoses
- Interventions
- Not listed
- Lead sponsor
- Genomas, Inc
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • Lexington, Kentucky
- Conditions
- Schizophrenia
- Interventions
- MK-8189, Placebo, Background AAP Therapy
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Bipolar Disorder
- Interventions
- Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- Not listed
- Enrollment
- 1,037,352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Interventions
- Lumateperone 42 mg, Risperidone 2 mg
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Schizophrenia
- Interventions
- perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 54
- States / cities
- Chula Vista, California • Los Angeles, California • Orange, California + 45 more
- Conditions
- Bipolar I Disorder
- Interventions
- Injectable Risperidone (Consta) or oral antipsychotic
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 4
- States / cities
- Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more